APUS
What one share of Apimeds Pharmaceuticals Us holds
Pharmaceutical Preparations
Corporation”). As a result of the Merger, MindWave became a direct wholly owned subsidiary of the Company. At the Effective
Apimeds Pharmaceuticals Us’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$40.20 |
|---|---|
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | −$9.21 |
| Cash and investments | $0.18 |
| Debt | $8.48 |
| Book value | $70.54 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$1.69 | — | −$1.37 | — | $0.04 |
| 2024 | — | −$1.76 | — | −$0.93 | — | −$1.72 |
| 2025 | — | −$5.51 | $0.05 | −$8.26 | — | $121.94 |